Elizabeth Anne Mullen, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Wilms Tumor | 41 | 2024 | 373 | 9.470 |
Why?
|
Kidney Neoplasms | 49 | 2024 | 4262 | 4.380 |
Why?
|
Ifosfamide | 1 | 2023 | 228 | 0.880 |
Why?
|
Carcinoma, Medullary | 5 | 2021 | 123 | 0.790 |
Why?
|
Nephrectomy | 16 | 2022 | 1050 | 0.720 |
Why?
|
Vincristine | 8 | 2023 | 1039 | 0.680 |
Why?
|
Carcinoma, Renal Cell | 6 | 2023 | 3143 | 0.550 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2016 | 604 | 0.520 |
Why?
|
Thrombocytopenia | 1 | 2023 | 1179 | 0.510 |
Why?
|
Liver Diseases | 1 | 2023 | 1253 | 0.500 |
Why?
|
Child | 46 | 2024 | 77709 | 0.500 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2023 | 11524 | 0.450 |
Why?
|
Income Tax | 1 | 2013 | 27 | 0.440 |
Why?
|
Medical Oncology | 3 | 2020 | 2265 | 0.440 |
Why?
|
BRCA2 Protein | 1 | 2016 | 794 | 0.400 |
Why?
|
Professional Practice | 1 | 2013 | 326 | 0.380 |
Why?
|
Kidney | 9 | 2023 | 7186 | 0.380 |
Why?
|
Ribonuclease III | 3 | 2020 | 275 | 0.380 |
Why?
|
Pediatrics | 4 | 2020 | 3475 | 0.370 |
Why?
|
Doxorubicin | 6 | 2024 | 2234 | 0.360 |
Why?
|
DEAD-box RNA Helicases | 3 | 2020 | 375 | 0.350 |
Why?
|
Dactinomycin | 5 | 2022 | 318 | 0.330 |
Why?
|
Neoplasm Staging | 17 | 2023 | 11031 | 0.330 |
Why?
|
Infant | 26 | 2023 | 35136 | 0.320 |
Why?
|
Rhabdoid Tumor | 2 | 2023 | 212 | 0.320 |
Why?
|
Child, Preschool | 30 | 2023 | 41006 | 0.320 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 1519 | 0.300 |
Why?
|
Anaplasia | 2 | 2024 | 16 | 0.300 |
Why?
|
Chromosomes, Human, Pair 1 | 3 | 2019 | 658 | 0.300 |
Why?
|
Loss of Heterozygosity | 3 | 2023 | 684 | 0.260 |
Why?
|
Guideline Adherence | 1 | 2016 | 2266 | 0.260 |
Why?
|
Etoposide | 2 | 2023 | 641 | 0.240 |
Why?
|
Precancerous Conditions | 2 | 2022 | 975 | 0.230 |
Why?
|
Judgment | 1 | 2006 | 281 | 0.230 |
Why?
|
Anger | 1 | 2006 | 402 | 0.230 |
Why?
|
Neoplasms | 5 | 2023 | 21683 | 0.230 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2024 | 9239 | 0.230 |
Why?
|
Morals | 1 | 2006 | 284 | 0.220 |
Why?
|
Sarcoma, Clear Cell | 1 | 2023 | 76 | 0.220 |
Why?
|
Hydrazines | 1 | 2024 | 226 | 0.210 |
Why?
|
Humans | 65 | 2024 | 744343 | 0.200 |
Why?
|
Social Justice | 1 | 2006 | 456 | 0.200 |
Why?
|
Food, Formulated | 1 | 2001 | 109 | 0.190 |
Why?
|
WAGR Syndrome | 1 | 2020 | 3 | 0.190 |
Why?
|
Combined Modality Therapy | 4 | 2023 | 8642 | 0.190 |
Why?
|
Thorax | 1 | 2023 | 547 | 0.190 |
Why?
|
Carboplatin | 1 | 2023 | 801 | 0.180 |
Why?
|
Child Nutrition Disorders | 1 | 2001 | 149 | 0.180 |
Why?
|
Lymphatic Metastasis | 6 | 2020 | 2924 | 0.180 |
Why?
|
Cyclophosphamide | 2 | 2023 | 2242 | 0.170 |
Why?
|
Intestinal Obstruction | 1 | 2023 | 424 | 0.170 |
Why?
|
Micronutrients | 1 | 2001 | 375 | 0.160 |
Why?
|
Triazoles | 1 | 2024 | 911 | 0.160 |
Why?
|
Rest | 1 | 2022 | 901 | 0.150 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 7913 | 0.150 |
Why?
|
Transposases | 1 | 2017 | 107 | 0.150 |
Why?
|
Cerebral Palsy | 1 | 2001 | 459 | 0.140 |
Why?
|
Chromosome Aberrations | 3 | 2022 | 1813 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 20129 | 0.140 |
Why?
|
Prognosis | 7 | 2023 | 29063 | 0.140 |
Why?
|
Survival Rate | 4 | 2024 | 12788 | 0.140 |
Why?
|
Sarcoma | 2 | 2020 | 1897 | 0.130 |
Why?
|
Infertility | 1 | 2022 | 655 | 0.130 |
Why?
|
Eligibility Determination | 1 | 2018 | 403 | 0.130 |
Why?
|
Haplotypes | 1 | 2021 | 2779 | 0.120 |
Why?
|
Physicians | 1 | 2013 | 4567 | 0.120 |
Why?
|
Adolescent | 19 | 2023 | 85781 | 0.120 |
Why?
|
Lymph Nodes | 2 | 2023 | 3474 | 0.120 |
Why?
|
Fanconi Anemia | 1 | 2016 | 319 | 0.120 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 1788 | 0.110 |
Why?
|
Contracts | 1 | 2013 | 60 | 0.110 |
Why?
|
Patient Selection | 2 | 2018 | 4215 | 0.110 |
Why?
|
Polycystic Kidney Diseases | 1 | 2014 | 133 | 0.110 |
Why?
|
Alleles | 2 | 2021 | 6933 | 0.110 |
Why?
|
Neoplasm Seeding | 1 | 2013 | 87 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2017 | 492 | 0.110 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1338 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4851 | 0.110 |
Why?
|
Medical Audit | 1 | 2013 | 467 | 0.100 |
Why?
|
History, 20th Century | 1 | 2020 | 2740 | 0.100 |
Why?
|
Female | 34 | 2022 | 380194 | 0.100 |
Why?
|
Prospective Studies | 9 | 2023 | 53288 | 0.100 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 895 | 0.100 |
Why?
|
Male | 33 | 2022 | 350118 | 0.100 |
Why?
|
Radiography, Abdominal | 1 | 2014 | 537 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7279 | 0.090 |
Why?
|
Clinical Protocols | 1 | 2016 | 1462 | 0.090 |
Why?
|
Mutation | 5 | 2021 | 29786 | 0.090 |
Why?
|
Neoplasm Invasiveness | 2 | 2017 | 3616 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2021 | 3479 | 0.090 |
Why?
|
Interdisciplinary Communication | 1 | 2015 | 950 | 0.090 |
Why?
|
Intraoperative Complications | 2 | 2013 | 1198 | 0.080 |
Why?
|
International Cooperation | 1 | 2015 | 1420 | 0.080 |
Why?
|
Diagnostic Imaging | 1 | 2022 | 3507 | 0.080 |
Why?
|
Repressor Proteins | 1 | 2019 | 3023 | 0.080 |
Why?
|
Tumor Burden | 1 | 2014 | 1915 | 0.080 |
Why?
|
Young Adult | 10 | 2023 | 56430 | 0.080 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 1941 | 0.080 |
Why?
|
Observer Variation | 1 | 2013 | 2593 | 0.070 |
Why?
|
Topotecan | 1 | 2007 | 137 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 35421 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 2942 | 0.070 |
Why?
|
Registries | 2 | 2020 | 8089 | 0.070 |
Why?
|
Biopsy | 2 | 2016 | 6756 | 0.070 |
Why?
|
Psychology, Social | 1 | 2006 | 51 | 0.070 |
Why?
|
Prevalence | 1 | 2023 | 15226 | 0.070 |
Why?
|
Pain, Postoperative | 2 | 2007 | 1643 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2014 | 1061 | 0.070 |
Why?
|
Chicago | 1 | 2006 | 240 | 0.070 |
Why?
|
RNA Interference | 3 | 2019 | 2889 | 0.070 |
Why?
|
Social Identification | 1 | 2006 | 103 | 0.060 |
Why?
|
Retrospective Studies | 10 | 2020 | 77449 | 0.060 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13102 | 0.060 |
Why?
|
Genetic Testing | 1 | 2018 | 3444 | 0.060 |
Why?
|
Disease-Free Survival | 4 | 2020 | 6895 | 0.060 |
Why?
|
Psychological Theory | 1 | 2006 | 168 | 0.060 |
Why?
|
Sensitivity and Specificity | 3 | 2015 | 14722 | 0.060 |
Why?
|
Crime | 1 | 2006 | 215 | 0.060 |
Why?
|
Cell Line, Tumor | 4 | 2024 | 16689 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2014 | 2564 | 0.060 |
Why?
|
Immunotherapy | 1 | 2020 | 4445 | 0.060 |
Why?
|
Incidence | 2 | 2020 | 20947 | 0.060 |
Why?
|
Karyopherins | 1 | 2024 | 137 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2019 | 1770 | 0.060 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2024 | 443 | 0.050 |
Why?
|
Genes, Wilms Tumor | 1 | 2022 | 94 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2019 | 2649 | 0.050 |
Why?
|
Ascorbic Acid Deficiency | 1 | 2001 | 24 | 0.050 |
Why?
|
Genomic Imprinting | 1 | 2023 | 328 | 0.050 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3508 | 0.050 |
Why?
|
DNA Breaks | 1 | 2021 | 49 | 0.050 |
Why?
|
Mice, Nude | 2 | 2019 | 3689 | 0.050 |
Why?
|
Biology | 1 | 2023 | 294 | 0.050 |
Why?
|
Vitamin A Deficiency | 1 | 2001 | 101 | 0.050 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 26 | 0.050 |
Why?
|
Time Factors | 6 | 2020 | 40075 | 0.050 |
Why?
|
Abortion, Induced | 1 | 2006 | 458 | 0.050 |
Why?
|
Nutritional Requirements | 1 | 2001 | 286 | 0.040 |
Why?
|
Treatment Outcome | 8 | 2020 | 63114 | 0.040 |
Why?
|
Nucleotides | 1 | 2022 | 464 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2024 | 871 | 0.040 |
Why?
|
Survivors | 2 | 2023 | 2291 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39050 | 0.040 |
Why?
|
Neoadjuvant Therapy | 2 | 2021 | 2728 | 0.040 |
Why?
|
Risk Factors | 8 | 2019 | 72290 | 0.040 |
Why?
|
Genotype | 2 | 2023 | 12951 | 0.040 |
Why?
|
Tissue Array Analysis | 1 | 2019 | 553 | 0.040 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2019 | 712 | 0.040 |
Why?
|
Chromosome Breakpoints | 1 | 2017 | 98 | 0.040 |
Why?
|
Zinc | 1 | 2001 | 684 | 0.040 |
Why?
|
Terminal Repeat Sequences | 1 | 2017 | 72 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2006 | 6365 | 0.040 |
Why?
|
Drug Therapy | 1 | 2020 | 497 | 0.040 |
Why?
|
Psychotherapy | 1 | 2006 | 1643 | 0.040 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2017 | 354 | 0.030 |
Why?
|
Motivation | 1 | 2006 | 1971 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 4 | 2021 | 17446 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 315 | 0.030 |
Why?
|
Enteral Nutrition | 1 | 2001 | 763 | 0.030 |
Why?
|
Apoptosis | 2 | 2024 | 9727 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 4933 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2085 | 0.030 |
Why?
|
Logistic Models | 4 | 2013 | 13408 | 0.030 |
Why?
|
Infant, Newborn | 4 | 2017 | 25625 | 0.030 |
Why?
|
Catalytic Domain | 1 | 2017 | 698 | 0.030 |
Why?
|
Phenotype | 3 | 2017 | 16365 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8428 | 0.030 |
Why?
|
Delirium | 1 | 2006 | 1609 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2021 | 1783 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 852 | 0.030 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2017 | 1723 | 0.030 |
Why?
|
Risk Assessment | 4 | 2019 | 23338 | 0.030 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2017 | 794 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 1581 | 0.030 |
Why?
|
Rupture, Spontaneous | 1 | 2013 | 354 | 0.030 |
Why?
|
North America | 1 | 2016 | 1249 | 0.030 |
Why?
|
Genomics | 2 | 2021 | 5720 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2022 | 2421 | 0.030 |
Why?
|
Translocation, Genetic | 1 | 2018 | 1420 | 0.030 |
Why?
|
Adult | 7 | 2020 | 214055 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3462 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2017 | 1097 | 0.030 |
Why?
|
Cognition Disorders | 1 | 2007 | 4043 | 0.030 |
Why?
|
Computer Systems | 1 | 2013 | 483 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2021 | 2703 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2017 | 1179 | 0.030 |
Why?
|
Sex Distribution | 1 | 2017 | 2297 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1758 | 0.030 |
Why?
|
Rupture | 1 | 2012 | 433 | 0.020 |
Why?
|
Disease Progression | 2 | 2019 | 13284 | 0.020 |
Why?
|
Age Distribution | 1 | 2017 | 2902 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 2012 | 0.020 |
Why?
|
Pain | 1 | 2006 | 4986 | 0.020 |
Why?
|
Cohort Studies | 4 | 2019 | 40561 | 0.020 |
Why?
|
Cell Cycle | 1 | 2019 | 2967 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2007 | 3674 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3647 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 2015 | 725 | 0.020 |
Why?
|
Cysts | 1 | 2015 | 678 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2019 | 4204 | 0.020 |
Why?
|
Survival Analysis | 2 | 2017 | 10252 | 0.020 |
Why?
|
DNA Methylation | 1 | 2023 | 4286 | 0.020 |
Why?
|
DNA | 1 | 2023 | 7301 | 0.020 |
Why?
|
Catheterization, Central Venous | 1 | 2014 | 514 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2017 | 1928 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 15076 | 0.020 |
Why?
|
Anemia, Sickle Cell | 1 | 2017 | 1018 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3521 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2013 | 973 | 0.020 |
Why?
|
Age of Onset | 1 | 2015 | 3271 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2019 | 21746 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2016 | 12245 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1504 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2020 | 3690 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9146 | 0.020 |
Why?
|
Peritoneal Neoplasms | 1 | 2013 | 665 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3597 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2017 | 6622 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2014 | 11366 | 0.020 |
Why?
|
Odds Ratio | 2 | 2013 | 9849 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 4186 | 0.020 |
Why?
|
Analgesia, Patient-Controlled | 1 | 2007 | 109 | 0.020 |
Why?
|
Mitochondria | 1 | 2019 | 3520 | 0.020 |
Why?
|
Proteomics | 1 | 2019 | 3638 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6538 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2007 | 892 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 12959 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5172 | 0.020 |
Why?
|
Pregnancy | 1 | 2006 | 29144 | 0.010 |
Why?
|
Research | 1 | 2012 | 1999 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2014 | 5078 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7729 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2013 | 2635 | 0.010 |
Why?
|
Area Under Curve | 1 | 2007 | 1654 | 0.010 |
Why?
|
Cell Line | 1 | 2017 | 15997 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2007 | 2274 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 15519 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12354 | 0.010 |
Why?
|
Mice | 2 | 2019 | 81183 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 12804 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2006 | 2971 | 0.010 |
Why?
|
Contrast Media | 1 | 2012 | 5300 | 0.010 |
Why?
|
Analgesics | 1 | 2006 | 1040 | 0.010 |
Why?
|
Interpersonal Relations | 1 | 2006 | 1425 | 0.010 |
Why?
|
Pain Measurement | 1 | 2006 | 3420 | 0.010 |
Why?
|
Animals | 2 | 2019 | 168757 | 0.010 |
Why?
|
Anesthesia | 1 | 2007 | 1561 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 19905 | 0.010 |
Why?
|
Disease Management | 1 | 2006 | 2459 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2007 | 10943 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 13695 | 0.010 |
Why?
|
United States | 1 | 2019 | 69872 | 0.010 |
Why?
|
Aged | 2 | 2007 | 163280 | 0.000 |
Why?
|
Postoperative Complications | 1 | 2006 | 15295 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2006 | 57776 | 0.000 |
Why?
|